169 related articles for article (PubMed ID: 28790306)
1. Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness.
Gonda K; Watanabe M; Tada H; Miyashita M; Takahashi-Aoyama Y; Kamei T; Ishida T; Usami S; Hirakawa H; Kakugawa Y; Hamanaka Y; Yoshida R; Furuta A; Okada H; Goda H; Negishi H; Takanashi K; Takahashi M; Ozaki Y; Yoshihara Y; Nakano Y; Ohuchi N
Sci Rep; 2017 Aug; 7(1):7509. PubMed ID: 28790306
[TBL] [Abstract][Full Text] [Related]
2. Development of a quantitative diagnostic method of estrogen receptor expression levels by immunohistochemistry using organic fluorescent material-assembled nanoparticles.
Gonda K; Miyashita M; Watanabe M; Takahashi Y; Goda H; Okada H; Nakano Y; Tada H; Amari M; Ohuchi N
Biochem Biophys Res Commun; 2012 Sep; 426(3):409-14. PubMed ID: 22959769
[TBL] [Abstract][Full Text] [Related]
3. A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study.
Hicks DG; Buscaglia B; Goda H; McMahon L; Natori T; Turner B; Soukiazian A; Okada H; Nakano Y
BMC Cancer; 2018 Dec; 18(1):1266. PubMed ID: 30563489
[TBL] [Abstract][Full Text] [Related]
4. Quantitative diagnosis of HER2 protein expressing breast cancer by single-particle quantum dot imaging.
Miyashita M; Gonda K; Tada H; Watanabe M; Kitamura N; Kamei T; Sasano H; Ishida T; Ohuchi N
Cancer Med; 2016 Oct; 5(10):2813-2824. PubMed ID: 27666577
[TBL] [Abstract][Full Text] [Related]
5. Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray.
Saito N; Matsuo T; Tsuda H; Yokota H; Okada H
PLoS One; 2024; 19(5):e0303614. PubMed ID: 38748758
[TBL] [Abstract][Full Text] [Related]
6. Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.
Ohkuma R; Miura S; Muto S; Toyomasu Y; Fujimoto Y; Ieguchi K; Onishi N; Shimizu T; Watanabe M; Takayanagi D; Goshima T; Horiike A; Hamada K; Ariizumi H; Shimokawa M; Hirasawa Y; Ishiguro T; Suzuki R; Iriguchi N; Tsurui T; Mura E; Takenoshita S; Numajiri K; Okabe N; Yoshimura K; Tsuji M; Kiuchi Y; Yajima T; Ishida H; Suzuki H; Yamochi T; Kobayashi S; Tsunoda T; Wada S
Front Immunol; 2023; 14():1260492. PubMed ID: 37790929
[TBL] [Abstract][Full Text] [Related]
7. Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging.
Gonda K; Miyashita M; Higuchi H; Tada H; Watanabe TM; Watanabe M; Ishida T; Ohuchi N
Sci Rep; 2015 Sep; 5():14322. PubMed ID: 26392299
[TBL] [Abstract][Full Text] [Related]
8. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
[TBL] [Abstract][Full Text] [Related]
9. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
11. Enzyme catalysis enhanced dark-field imaging as a novel immunohistochemical method.
Fan L; Tian Y; Yin R; Lou D; Zhang X; Wang M; Ma M; Luo S; Li S; Gu N; Zhang Y
Nanoscale; 2016 Apr; 8(16):8553-8. PubMed ID: 26786242
[TBL] [Abstract][Full Text] [Related]
12. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
13. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
[TBL] [Abstract][Full Text] [Related]
14. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
16. Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
Scheel AH; Penault-Llorca F; Hanna W; Baretton G; Middel P; Burchhardt J; Hofmann M; Jasani B; Rüschoff J
Diagn Pathol; 2018 Mar; 13(1):19. PubMed ID: 29530054
[TBL] [Abstract][Full Text] [Related]
17. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
18. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
19. Automated Quantification of Extranuclear ERα using Phosphor-integrated Dots for Predicting Endocrine Therapy Resistance in HR
Guo Z; Tada H; Kitamura N; Hamada Y; Miyashita M; Harada-Shoji N; Sato A; Hamanaka Y; Tsuboi K; Harada N; Takano-Kasuya M; Okada H; Nakano Y; Ohuchi N; Hayashi SI; Ishida T; Gonda K
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31013810
[TBL] [Abstract][Full Text] [Related]
20. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
